Technology

NANOZOLID® TECHNOLOGY PLATFORM

NanoZolid® – a unique proprietary technology

NanoZolid® (NZ) is a safe, flexible and functional method of delivering drugs. When injected, NanoZolid forms a solid depot releasing the active drug over a period of up to six months. As it releases its drug load, the NanoZolid® depot dissolves and is absorbed harmlessly into the body.

NanoZolid® overcomes many of the issues that impact on the effectiveness of treatments and patient quality of life. It reduces the requirements for frequent dosing while retaining the efficacy of the original drug compound with reduced the side effects. NanoZolid® reduces patient discomfort, improves compliance and reduces healthcare costs.

NanoZolid® is compatible with molecules from small to larger sizes and can be a drug delivery alternative in most therapy areas where a controlled and sustained release is preferred.

The controlled release of drug compounds can be tailored to the needs of the patient, disease and drugs being used:

NanoZolid® patented technology uses thirteen different manufacturing steps to provide the controlled and extended release of the drug. The GMP manufacturing process is based on nano-crystallization, using a combination of hydrating ceramics, water and pressure. Partnering with Recipharm, LIDDS has produced drug product on an industrial scale for Liproca® Depot.

NANOZOLID® APPLICATIONS

A technology with many applications

NanoZolid® has many applications and can be tailored to the needs to the patient, the disease being treated and the drug formulations being used.

The technology’s potential is confirmed in phase II and LIDDS continues to identify future areas of therapy that would benefit from controlled drug release.

In August 2018, the Journal of Drug Delivery Science and Technology published a scientific article entitled “Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release formulations”. The article describes the processes behind the NanoZolid® technology. Link to the article

Patent portfolio

A total of 89 national patents have so far been granted within eight patent families and LIDDS now has comprehensive patent protection for the NanoZolid® platform in all major markets. There are only a few remaining countries where applications have not yet been granted. These are markets where the processing time for patent applications is usually long.

The patent portfolio is judged to be sound and includes methods for controlling drug release, the manufacturing process, injection devices/aids, the method for controlling the solidification rate and the principle for treating prostate cancer with the NanoZolid® technology.

The European Patent Office has approved a novel patent for NanoZolid® that provides patent protection until 2037 for both the LIDDS technology platform and for the drugs developed in combination with NanoZolid®.

In addition to patent protection, data exclusivity can be granted to LIDDS, applying between 2027 and 2030, which can result in up to 10 years of additional market exclusivity after product registration.

During the first quarter of 2017, LIDDS filed a patent application to protect the development of NanoZolid® with immune-modulating drugs and immunotherapy methods, as initial research demonstrated that the technology can integrate larger biomolecules. Another patent application was submitted in October 2017 regarding the method of local treatment with cytostatics in combination with immunotherapy.

PATENT

PATENT

US

EU

REST OF THE WORLD

1 / 2004

Bioceramic compositions

Approved

Approved

Not filed

2 / 2006

Method to treat prostate cancer

Approved

Approved

Aus, Can, Chi, Jap, Mex, Russ, S Kor, Nor, Afr, Isr, Ind

3 / 2007

Slow local drug release

Approved

Approved

Aus, Can, Chi, HK, Jap, Mex, Russ, S Kor, Isr, S. Afr, Ind

4 / 2009

Mixing tool suspensions

Approved

Approved

Aus, Can, Chi, Russ, Isr, Jap, Mex, S Korea, Ind, S. Afr

5 / 2009

Steering of curing

Approved

Approved

Aus, Can, Russ, Jap, HK, Mex, S.Kor, Isr, Ind, S. Afr

6 / 2016

Manufacturing process

Filed

Approved

-

7 / 2017

NanoZolid + STING

-

Filed

-

Lidds

LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.